We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of JAMA |

Highlights FREE

JAMA. 2016;315(4):323-325. doi:10.1001/jama.2015.14071.
Text Size: A A A
Published online


Observational data suggest that increased vitamin D intake during pregnancy may reduce the risk of wheezing in early childhood. In a clinical trial examining this relationship, Chawes and colleagues randomly assigned 623 women to receive vitamin D3 (2400 IU/d) or placebo beginning in pregnancy week 24 and continued through 1 week postpartum. All women received 400 IU/d of vitamin D3 as part of usual pregnancy care. The authors report that compared with 400 IU/d of vitamin D3, use of 2800 IU/d did not result in a statistically significantly reduced risk of persistent wheeze in their offspring through age 3 years.

Editorial and Related Article

In a randomized trial involving 881 pregnant women, Litonjua and colleagues assessed whether prenatal vitamin D supplementation—4400 IU/d compared with 400 IU/d—can prevent asthma or recurrent wheeze in early childhood. The authors found that compared with vitamin D 400 IU/d—the amount in a prenatal vitamin—supplementation with 4400 IU/d significantly increased vitamin D levels in the women but was not associated with a significantly lower incidence of asthma or recurrent wheeze in their children through 3 years of age. In an Editorial, von Mutius and Martinez discuss inconclusive findings from clinical trials of prenatal vitamin D supplementation for early childhood asthma prevention.

Editorial and Related Article

In a 3-group open-label randomized trial involving 1086 adult smokers motivated to quit smoking, Baker and colleagues assessed the comparative efficacy of 12 weeks’ treatment with the nicotine patch, varenicline, or combination nicotine replacement (nicotine patch and nicotine lozenge) for smoking cessation. The authors found the 3 treatments produced comparable rates of smoking abstinence at 26 weeks’ follow-up.


This US Preventive Services Task Force (USPSTF) Recommendation Statement by Siu and colleagues addresses screening for depression in adults. The USPSTF recommends screening for depression in the general adult population, including older adults and pregnant and postpartum women. Summary findings from the USPSTF evidence review of the benefits and harms of screening for depression in adults; the accuracy of depression screening instruments; and the benefits and harms of treatment are presented. In an Editorial, Thase discusses progress and unrealized potential in primary care screening and treatment for depression.

Editorial 1 and 2 and Related Article, and JAMA Patient Page

This Evidence Report for the US Preventive Services Task Force by O’Connor and colleagues summarizes the evidence relating to benefits and harms of depression screening and treatment in pregnant and postpartum women and evidence relating to the diagnostic accuracy of selected depression screening instruments in this population.

Editorial 1 and 2, Related Article


Longitudinal studies often include multiple, repeated measurements from each study participant, which are more likely to be similar to each other than measurements from different patients—a correlation to consider in analyses of the study data. This JAMA Guide to Statistics and Methods article by Detry and Ma discusses advantages and limitations of mixed-model analysis, a method that accounts for factors assumed to be the same and those likely to vary substantially across a cohort of patients.

This JAMA Clinical Evidence Synopsis by Tramacere and colleagues summarizes a Cochrane review (39 clinical trials; 25 113 patients total) of immunotherapies for relapsing-remitting multiple sclerosis (MS). Immunotherapies associated with the greatest benefit for relapse prevention and those with the highest risk of discontinuation due to adverse events were identified.



Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.